Page 56 - GPD-3-4

Gene & Protein in Disease Immune checkpoint blocker and NK cell activation

programmed death 1 ligands by murine T cells and APC. 67. Ding G, Shen T, Yan C, Zhang M, Wu Z, Cao L. IFN-γ
J Immunol. 2002;169(10):5538-5545. down-regulates the PD-1 expression and assist nivolumab in
doi: 10.4049/jimmunol.169.10.5538 PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic
cancer. BMC Cancer. 2019;19(1):1053.
57. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1
immunoinhibitory receptor by a novel B7 family member doi: 10.1186/s12885-019-6145-8
leads to negative regulation of lymphocyte activation. J Exp 68. Lai X, Hao W, Friedman A. TNF-α inhibitor reduces drug-
Med. 2000;192(7):1027-1034. resistance to anti-PD-1: A mathematical model. PLoS One.
doi: 10.1084/jem.192.7.1027 2020;15(4):e0231499.
58. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member doi: 10.1371/journal.pone.0231499
of the B7 family, co-stimulates T-cell proliferation and 69. Keir ME, Liang SC, Guleria I, et al. Tissue expression of
interleukin-10 secretion. Nat Med. 1999;5(12):1365-1369. PD-L1 mediates peripheral T cell tolerance. J Exp Med.
doi: 10.1038/70932 2006;203(4):883-895.
59. Dong H, Strome SE, Salomao DR, et al. Tumor-associated doi: 10.1084/jem.20051776
B7-H1 promotes T-cell apoptosis: A potential mechanism of 70. Darvin P, Sasidharan Nair V, Elkord E. PD-L1 expression in
immune evasion. Nat Med. 2002;8(8):793-800. human breast cancer stem cells is epigenetically regulated
doi: 10.1038/nm730 through posttranslational histone modifications. J Oncol.
2019;2019:3958908.
60. Trabattoni D, Saresella M, Biasin M, et al. B7-H1 is
up-regulated in HIV infection and is a novel surrogate marker doi: 10.1155/2019/3958908
of disease progression. Blood. 2003;101(7):2514-2520. 71. Takada K, Toyokawa G, Okamoto T, et al. A comprehensive
doi: 10.1182/blood-2002-10-3065 analysis of programmed cell death ligand-1 expression with
the clone SP142 antibody in non-small-cell lung cancer
61. Zheng Y, Fang YC, Li J. PD-L1 expression levels on tumor patients. Clin Lung Cancer. 2017;18(5):572-582.e1.
cells affect their immunosuppressive activity. Oncol Lett.
2019;18(5):5399-5407. doi: 10.1016/j.cllc.2017.02.004
doi: 10.3892/ol.2019.10903 72. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K,
Ueda S. Overexpression of B7-H1 (PD-L1) significantly
62. Latchman YE, Liang SC, Wu Y, et al. PD-L1-deficient mice associates with tumor grade and postoperative prognosis
show that PD-L1 on T cells, antigen-presenting cells, and in human urothelial cancers. Cancer Immunol Immunother.
host tissues negatively regulates T cells. Proc Natl Acad Sci 2007;56(8):1173-1182.
U S A. 2004;101(29):10691-10696.
doi: 10.1007/s00262-006-0266-z
doi: 10.1073/pnas.0307252101
73. Schiwitza A, Schildhaus HU, Zwerger B, et al. Monitoring
63. Torphy RJ, Schulick RD, Zhu Y. Newly emerging immune efficacy of checkpoint inhibitor therapy in patients with non-
checkpoints: Promises for future cancer therapy. Int J Mol small-cell lung cancer. Immunotherapy. 2019;11(9):769-782.
Sci. 2017;18(12):2642.
doi: 10.2217/imt-2019-0039
doi: 10.3390/ijms18122642
74. Mager L, Gardeen S, Carr DR, Shahwan KT. Cemiplimab
64. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. for the treatment of advanced cutaneous squamous cell
SHP-1 and SHP-2 associate with immunoreceptor tyrosine- carcinoma: Appropriate patient selection and perspectives.
based switch motif of programmed death 1 upon primary Clin Cosmet Investig Dermatol. 2023;16:2135-2142.
human T cell stimulation, but only receptor ligation prevents
T cell activation. J Immunol. 2004;173(2):945-954. doi: 10.2147/ccid.s381471
doi: 10.4049/jimmunol.173.2.945 75. Lantuejoul S, Damotte D, Hofman V, Adam J. Programmed
death ligand 1 immunohistochemistry in non-small cell
65. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 lung carcinoma. J Thorac Dis. 2019;11(Suppl 1):S89-S101.
and PD-1 receptors inhibit T-cell activation by distinct
mechanisms. Mol Cell Biol. 2005;25(21):9543-9553. doi: 10.21037/jtd.2018.12.103
doi: 10.1128/mcb.25.21.9543-9553.2005 76. Atkins MB, Tannir NM. Current and emerging therapies
for first-line treatment of metastatic clear cell renal cell
66. Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory
pathway affects both CD4(+) and CD8(+) T cells and is carcinoma. Cancer Treat Rev. 2018;70:127-137.
overcome by IL-2. Eur J Immunol. 2002;32(3):634-643. doi: 10.1016/j.ctrv.2018.07.009
doi: 10.1002/1521-4141(200203)32:3<634::aid- 77. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for
immu634>3.0.co;2-9 first-line treatment of PD-L1-selected patients with NSCLC.

Volume 3 Issue 4 (2024) 8 doi: 10.36922/gpd.3804